At the time of writing, MoonLake Immunotherapeutics [MLTX] stock is trading at $41.16, up 5.51%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MLTX shares have gain 5.73% over the last week, with a monthly amount drifted -0.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on May 19, 2025, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $61 for it. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $67. On January 17, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $82 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Oppenheimer started tracking with a Outperform rating for this stock on June 25, 2024, and assigned it a price target of $104. In a note dated April 02, 2024, Goldman initiated an Neutral rating and provided a target price of $62 on this stock.
For the past year, the stock price of MoonLake Immunotherapeutics fluctuated between $31.42 and $58.26. Currently, Wall Street analysts expect the stock to reach $67 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $41.16 at the most recent close of the market. An investor can expect a potential return of 62.78% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at -1210.31%, Pretax Profit Margin comes in at -1447.84%, and Net Profit Margin reading is -1428.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.0 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.74 points at the first support level, and at 38.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.88, and for the 2nd resistance point, it is at 42.61.
Ratios To Look Out For
It is important to note that MoonLake Immunotherapeutics [NASDAQ:MLTX] has a current ratio of 21.11. Further, the Quick Ratio stands at 21.11, while the Cash Ratio is 11.32.
Transactions by insiders
Recent insider trading involved BVF PARTNERS L P/IL, Director, that happened on Oct 04 ’24 when 2.0 million shares were sold. Director, Sturge Simon completed a deal on Oct 04 ’24 to sell 0.17 million shares.
